Michael Loughnane, managing partner, has more than 30 years’ experience practicing intellectual property law. He has significant experience leading complex patent and trade secret litigation in the district and federal courts, and counsels clients on issues of patent validity and infringement. He also has extensive experience in the drafting and prosecution of patent applications and provides guidance to clients introducing new products to the market.

Mr. Loughnane has represented clients in matters involving a wide range of industries, including life sciences, biotechnology and pharmaceutical, medical device, and environmental. His clients have included AkzoNobel, Intervet, Schering-Plough, BASF, and Teva.

He is also a member of the firm’s Management and Executive Committees.

Representative Experience

  • AkzoNobel in a patent infringement case filed by Akzo against Dow Chemicals and involving Akzo’s patented process for the creation of aqueous polymer dispersions. AkzoNobel v. Dow Chemicals (D. Del.).

  • AkzoNobel in patent litigation brought by A.L.M. Holding relating to asphalt compositions. A.L.M. Holding v. AkzoNobel (D. Del.).

  • Schering-Plough in litigations related to a DNA-subunit vaccine against a porcine virus. These settled on favorable terms. Wyeth v. Intervet (D. Del.).

  • Teva in litigations against Pfizer regarding Gabapentin, Teva’s AB-rated generic equivalent to Pfizer’s Neurontin®. The settlement agreement ending this case was reached just two weeks into a jury trial that had been scheduled to last seven weeks. Warner-Lambert Company et al. v. Purepac Pharmaceutical et al.  (D. NJ).
Representative Matters
  • AkzoNobel in a patent infringement case filed by Akzo against Dow Chemicals and involving Akzo’s patented process for the creation of aqueous polymer dispersions. AkzoNobel v. Dow Chemicals (D. Del.).
  • AkzoNobel in patent litigation brought by A.L.M. Holding relating to asphalt compositions. A.L.M. Holding v. AkzoNobel (D. Del.).
  • Schering-Plough in litigations related to a DNA-subunit vaccine against a porcine virus. These settled on favorable terms. Wyeth v. Intervet (D. Del.).
  • Teva in litigations against Pfizer regarding Gabapentin, Teva’s AB-rated generic equivalent to Pfizer’s Neurontin®. The settlement agreement ending this case was reached just two weeks into a jury trial that had been scheduled to last seven weeks. Warner-Lambert Company et al. v. Purepac Pharmaceutical et al.  (D. NJ).
Bar and Court Admissions
  • New Jersey
  • New York
  • U.S. Court of Appeals for the Federal Circuit
  • Registered Patent Attorney: U.S. Patent and Trademark Office
Professional Organizations
  • American Bar Association
  • New Jersey Intellectual Property Law Association
  • New York Intellectual Property Law Association